Here we show that inhibition of Notch1 by a novel, selective neutralizing monoclonal antibody (anti-N1) developed in our laboratory, delays melanoma growth; promotes an inflamed TME which enhances the efficacy of anti-PD1; and is devoid of the side effects observed with GSI. Here, PDCD1 is linked to melanoma.